What does this research mean for the field?

Early use of palbociclib combined with endocrine therapy and anti-HER2 antibody improves progression-free survival in HR+/HER2+ advanced breast cancer patients. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to evaluate the effectiveness of combining CDK4/6 inhibitors and endocrine therapy with anti-HER2 antibody in treating HR+/HER2+ metastatic breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS5-02-02: Early use of CDK4/6 inhibitor combined with endocrine therapy plus anti-HER2 antibody may get more survival benefit in HR+/HER2+ advanced breast cancer: result from a phase II single-arm mini cohort study (CABC016)

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the effectiveness of combining CDK4/6 inhibitors and endocrine therapy with anti-HER2 antibody in treating HR+/HER2+ metastatic breast cancer.
Phase II, single-arm, prospective cohort study design.
Participants received palbociclib with trastuzumab or inetetamab and endocrine therapy in a specific schedule.
Primary endpoint was progression-free survival (PFS), with secondary endpoints including safety and overall response rate.
Median PFS for the intention-to-treat population was 16.5 months.
Patients naive to endocrine therapy had significantly improved PFS compared to those previously treated (22.0 months vs. 8.3 months).
Overall response rate was 34.1%, increasing to 45.5% in ET-naive patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase II study shows improved survival in HR+/HER2+ breast cancer using CDK4/6 inhibitor with endocrine therapy and anti-HER2 antibody, suggesting a promising treatment approach.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6996a83eecb39a600b3eeb0f https://doi.org/10.1158/1557-3265.sabcs25-ps5-02-02

View Full Paper

Ask AI

Bookmark

Implication

Phase II study shows improved survival in HR+/HER2+ breast cancer using CDK4/6 inhibitor with endocrine therapy and anti-HER2 antibody, suggesting a promising treatment approach.

Abstract PS5-02-02: Early use of CDK4/6 inhibitor combined with endocrine therapy plus anti-HER2 antibody may get more survival benefit in HR+/HER2+ advanced breast cancer: result from a phase II single-arm mini cohort study (CABC016)

Key Points

Discussion

Implication

Cite This Study

Abstract PS5-02-02: Early use of CDK4/6 inhibitor combined with endocrine therapy plus anti-HER2 antibody may get more survival benefit in HR+/HER2+ advanced breast cancer: result from a phase II single-arm mini cohort study (CABC016)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider